Solid Tumor Targeting CAR-T Development Service through PLGA Microneedle Patch (PMN)

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service, utilizing a PLGA Microneedle Patch (PMN), is designed to overcome poor T-cell infiltration, limited therapeutic windows, and high local recurrence rates in solid tumor therapy. By combining advanced polymeric microneedle engineering with cell seeding technology, this platform enables the direct and sustained delivery of CAR-T cells into the tumor microenvironment, thereby enhancing local persistence and anti-tumor activity. This next-generation approach accelerates translational development and maximizes therapeutic efficacy in challenging solid tumor indications.

Introduction

The successful application of CAR T therapy to solid tumors is highly dependent on achieving sufficient T cell concentration and distribution to penetrate the dense tumor microenvironment (TME) and prevent recurrence. The PMN is a robust, biocompatible device that bypasses the TME's physical barriers by physically seeding viable CAR T cells across the tumor site. This localized, multi-point delivery enhances T cell infiltration and subsequent activation, as demonstrated by the increase in local cytokine levels and T cell persistence in pre-clinical models.

Creative Biolabs' PLGA Microneedle Patch

Our service provides a comprehensive, end-to-end solution for integrating your proprietary CAR T cell construct into a clinically relevant localized delivery system, moving beyond the limitations of systemic administration. We address the fundamental biomechanical challenge of solid tumor penetration by delivering viable, highly-functional cells directly into the treatment site (post-resection cavity or primary lesion) in a homogenous, multi-point fashion.

• Overcoming the Physical Barrier: The PMN physically breaches the dense extracellular matrix (ECM) of the solid tumor, allowing CAR-T cells to be scattered evenly throughout the site, rather than being restricted to the injection channel seen in conventional intra-tumoral delivery.
• Maximizing Local Concentration: By placing the therapeutic cells directly at the target site, the PMN minimizes T-cell dilution and degradation in the bloodstream, ensuring a high delivery, but also guarantees enhanced patient quality of life and compliance.

Discover How We Can Help - Request a Consultation.

What We Can Offer

• Active Scattered Seeding

  Our PMN array facilitates multi-point delivery across a large surface area, achieving highly homogeneous cell distribution compared to the confined pooling seen with single-point injection.

• Enhanced Cell Protection

  The porous PLGA matrix shields sensitive T cells from shear stress and friction during tissue insertion, ensuring maximum cell viability and therapeutic function upon release.

• Superior Persistence and Function

  PMN-mediated delivery results in to increase in T cell proliferation and persistence in the tumor microenvironment compared to traditional injection, directly translating to enhanced anti-tumor efficacy against both melanoma and pancreatic tumor models.

Our Workflow

The final deliverables include the PMN CAR-T master batch report with QC data, an in vivo efficacy data package detailing tumor recurrence and T cell infiltration, and a detailed manufacturing protocol suitable.

Core Benefits

• Proven Scattered Seeding: Our platform enables homogeneous CAR-T cell distribution, leading to a 3-fold increase in T-cell expansion within tumors compared to standard injection.
• Maximized Cell Viability: Our gentle vacuum-loading and protective pore structure ensure >95% cell viability post-loading, guaranteeing that potent, functional cells reach the tumor bed.
• Tailored and Scalable: We customize the patch geometry for your specific tumor type and have developed a scalable fabrication process that aligns with pre-clinical development needs.

Data Support

This study introduces an innovative method to improve CAR-T cell therapy for solid tumors. Researchers developed a porous microneedle patch that can be loaded with CAR-T cells and implanted directly into a tumor site. This technology allows for a more effective and evenly distributed delivery of the cells compared to standard injection. The approach enhances CAR-T cell infiltration and anti-tumor activity.

Fig.1 Characterization of porous microneedle (PMN) patches for CAR-T cell loading and delivery.¹

FAQs

Partner with Us

Creative Biolabs provides a specialized Solid Tumor Targeting CAR-T Development Service that integrates your engineered T-cells with our proprietary PMN technology. This synergistic solution directly addresses the critical challenge of poor T-cell infiltration in solid tumors, delivering superior distribution, enhanced persistence, and potent antitumor efficacy in pre-clinical models, and de-risking your path to clinical translation. Ready to enhance your solid tumor CAR-T project with our advanced delivery platform? Our team of experts is ready to discuss your specific requirements and design a collaborative project plan. Contact us today to accelerate your novel therapeutic pipeline through our cutting-edge microneedle delivery platform.

Reference

1. Li, Hongjun et al. "Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy." National Science Review vol. 9,3 nwab172. 21 Sep. 2021. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1093/nsr/nwab172